Envelope-Targeting Antiviral Compounds for Mutation-Resistant Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral treatments are specific to a single virus or a small subset of viruses, are susceptible to rapid genetic mutation, and often require multiple doses due to weak immune responses, lacking a broad mechanism of action that is resistant to viral mutation and immune evasion.
Innovation Solution
Development of antiviral compounds that target the viral envelope through cationic or zwitterionic amphipathic helices, disrupting viral entry and inducing a robust immune response, potentially providing long-lasting protection against a wide range of enveloped viruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral medications target specific viral proteins or mechanisms, then treatment effectiveness against that specific virus is improved, but the treatment becomes susceptible to genetic mutation and viral evasion
Solution Approach 1:
The patent applies universality by designing antiviral compounds that target the viral envelope structure, which is a common feature across multiple virus families including coronaviruses, influenza viruses, and paramyxoviruses. The compound of formula (I) with its cationic or zwitterionic amphipathic helix structure can interact with the conserved envelope components, providing broad-spectrum antiviral activity that is not easily evaded by genetic mutation of specific viral proteins.
2Reliability
If current antiviral treatments are designed for specific virus targets, then specificity of action is improved, but the scope of viruses covered is limited
Solution Approach 1:
The compound of formula (I) achieves multi-functionality by targeting the viral envelope, a structure present in enveloped viruses from different families. The cationic or zwitterionic amphipathic helix can interact with the lipid bilayer and envelope proteins simultaneously, providing broad coverage against coronaviruses, influenza viruses, paramyxoviruses, and other enveloped viruses while maintaining antiviral specificity.
Solution Approach 2:
The antiviral compound employs a composite molecular structure combining cationic or zwitterionic groups with amphipathic helical regions. This composite design allows the molecule to interact with multiple components of the viral envelope (lipid bilayer and proteins) simultaneously, enhancing both broad-spectrum coverage and mechanism-specific action.
3Duration of action of stationary object
If live-attenuated virus vaccines are used to produce robust immune response, then protection duration is improved, but risk of viral reversion to active form increases
Solution Approach 1:
The patent uses a small molecule compound of formula (I) as an intermediary that mimics viral envelope components and triggers immune response without containing actual viral genetic material. This mediator approach provides robust immune stimulation similar to live-attenuated vaccines but eliminates the reversion risk by using a non-replicating chemical compound instead of modified virus.
4Object-affected harmful factors
If chemically inactivated virus vaccines are used to eliminate infection risk, then safety is improved, but immune response robustness deteriorates
Solution Approach 1:
The compound of formula (I) changes the parameter of immune recognition by presenting viral envelope-like structures in a stable, non-inactivating form. The cationic or zwitterionic amphipathic helix maintains structural features that are immunogenic while being chemically stable and non-infectious, thereby achieving both safety and robust immune response without the limitations of chemical inactivation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inactivate multiple enveloped viruses, including SARS-CoV-2 variants, reduce viral load, and induce a broadly neutralizing immune response, offering protection against both homologous and heterologous strains.
Implementation Method 1
the peptide may form a cationic or zwitterionic amphipathic helix
Implementation Method 2
the peptide may form a cationic or zwitterionic amphipathic helix that may comprise an amino acid sequence
Data Source
AI summary
The current disclosure provides methods for the production of ‘vaccine-like’ antiviral preparations. The present disclosure provides compounds for the treatment of a wide range of enveloped viral diseases and conditions. The present disclosure further provides methods for treating, preventing, and/or suppressing an enveloped virus disease in a subject using the compounds disclosed herein as well as pharmaceutical compositions comprising such compound.